Information Emavusertib (CA-4948) Emavusertib (CA-4948) is a potent and orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4/FMS-like Tyrosine Kinase 3 (IRAK4/FLT3) with anti-tumor activity. Targets IRAK4 ; FLT3 In vitro Emavusertib (CA-4948) is over 500-fold more selective for IRAK-4 compared to IRAK-1. Emavusertib (CA-4948) reduces TNF-α, IL-1β, IL-6 and IL-8 release from TLR-Stimulated THP-1 Cells with an IC50 In vivo Emavusertib (CA-4948) has anti-tumour activity in animal models including tumours containing MyD88 gene mutations. Cell Research(from reference) Cell lines：THP-1 cells Concentrations：0.1 μM-10 μM Incubation Time：60 min